Status:
COMPLETED
Study Evaluating Sirolimus in Kidney Transplant Recipients
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Graft vs Host Disease
Kidney Transplantation
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to compare the kidney function in patients who have received a transplanted kidney and were treated with the combination of sirolimus, daclizumab, mycophenolate and cortic...
Eligibility Criteria
Inclusion
- Kidney transplantation
- Donor must be at least 60 years old.
Exclusion
- Current systemic infection
- Unstable angina or treatment for serious arrhythmia.
- Cancer within the previous 5 years.
Key Trial Info
Start Date :
November 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2008
Estimated Enrollment :
61 Patients enrolled
Trial Details
Trial ID
NCT00195273
Start Date
November 1 2004
End Date
July 1 2008
Last Update
April 28 2010
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Oslo, Norway, N-0027
2
Gothenburg, Sweden, SE-413 45
3
Uppsala, Sweden, SE-751 85